Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB,

… 3 study of B-VEC for the treatment of dystrophic epidermolysis bullosa (DEB) based on feedback from the U.S. Food and Drug Administration (FDA)., … 3 study of B-VEC for the treatment of dystrophic epidermolysis bullosa (DEB) based on feedback from the U.S. Food and Drug Administration (FDA)., Read More

Scroll to Top